|
 
- 积分
- 414
- 威望
- 414
- 包包
- 645
|
本帖最后由 细胞海洋 于 2014-1-4 09:43 编辑 ) v" v- S. J) F- O
% H, g% |* @$ P8 y2 SMolecular therapies5 l0 R9 T$ i2 I$ V3 W, `9 s& r
Dr. Zoltán Balajthy, Dr. János Aradi, Dr. Zoltán Balajthy, Dr. Éva Csősz, Dr. Beáta Scholtz, Dr. István Szatmári, Dr. József Tőzsér, Dr. Tamás Varga (2011)& W. f+ \2 S- u' B8 D
: k! L4 F/ ~3 }$ e. k- H
University of Debrecen
6 f; D! V$ ]5 i- O6 [% BCopyright © 2011 The project is funded by the European Union and co-financed by the European Social Fund., Manuscript completed: 17 November 2011
, f& x* A/ @( c) _7 z! C: I B9 T) f; ^8 |+ _3 }
6 ?& Q+ A2 A$ c5 x2 X s, y
" K. p" G+ _! Z9 w3 [/ jIndex/ D, N0 i, G1 O
1. 1. Functional Genomics; [6 x6 s* b1 ^# a! W; a, _( D/ L
1.1 Definitions O" ? E* h( j6 G
1.2 About diseases
9 h: ]% @. n2 @6 J* o) W1.3 Approaches to understanding disease mechanisms. m, I! F& |8 V1 \7 C
1.3.1 Gene expression is regulated in several basic ways
& O) k' n7 W' U; f1.3.2 Microarrays: functional genomics in cancer research1 U$ c, w+ s0 J8 S
1.3.3 A Variety of Genetic Alterations Underlie Developmental Abnormalities and Disease( T# k/ E9 j. n/ Y* I
1.3.4 Genomic microarrays& I1 i" F& }+ }* G5 ~$ z v9 R! T! F- T, G
2. 2. Recombinant proteins
- \2 u" G b5 W0 y2 R, I: d2.1 Overview: Protein pharmaceuticals Z4 m' ^; v: N
2.2 Cell-free systems: In vitro transcription and translation/ B+ [- ?. n; ~; _/ Z3 E/ y( o: }
2.3 Recombinant protein expression in isolated cells (cell culture); w3 ^3 B: |4 a4 X; c
2.4 Non-prokaryotic expression systems, {. g) i' ^/ Y$ @: D1 U
2.4.1 Cloning in Pichia pastoris
. J% ]% j' P0 Z) c" Y" \ ^2.4.2 Baculovirus mediated protein expression in insect cells( b# M4 S% R% E
2.4.3 Mammalian expression systems7 H% X3 m d7 i ~
2.5 Purification of recombinant proteins
/ P' U1 T$ S# Z% j2 A3. 3. Gene Therapy: Vectors and Strategies.
9 U/ q6 q5 x9 V' U" _- s+ [' a3.1 Vectors for Gene Therapy6 F1 w( Y! d: \ s+ r- b: k
3.2. Types of gene transfer, vectors for gene therapy
6 S5 T4 I$ `/ ^0 L5 o( J0 g; _5 N3.3. General gene therapy strategies+ ~( T2 j& \1 p
3.4. Human gene therapy
4 X' L j! j2 t) m) M( ] v4. 4. Protein replacement therapies.) F2 Y4 [$ k+ e j
5. 5. Recombinant antibodies and the phage display technology
! x3 z, F) L$ H) x/ K5.1. Introduction
- @) V2 ~, _; w5.1.1. The structure of antibodies and their production in the body
# d& c5 A& j. {9 v; u1 _5.1.2. Antigen-antibody binding
; W0 J1 V/ c0 O5.2. The production of therapeutic antibodies
5 | g/ B9 i' Z, c+ j/ m5 ?+ r/ u. O5.2.1. The production of antibodies in hybridoma cells.$ }* O# G1 L) c) J. w0 C
5.2.2. Humanized antibodies# p& a* y, L2 G- F/ q) [
5.2.3. Production of human antibodies: N/ J0 Z! `5 P
5.3. Generation of antibodies by phage display
1 P! T+ T7 {3 i5.3.1. The phage display technology2 p% e/ m$ }: [9 C$ O
5.3.2. Generation of phage libraries
0 L1 l. A( z9 T8 @4 ?% a6 |/ _5.4. Administration of therapeutic antibodies- q( u- ~$ D: l" B2 X
6. 6. Anti-cytokine Therapy (sepsis).
+ A- \5 l! t% y& S1 O2 f a! Y6.1. The consequences of developing inflammation
# c0 |: E: f9 d5 g) |/ W/ g' X6.2. Development of Inflammatory Response: Synthesis of Lipid Mediators; A: `, J: c' y& |' F9 \7 S
6.3. Role of the Liver in Maintenance of Homeostasis: Acute Phase Response. P2 M: K8 y3 n0 [6 H! r/ X
6.4. Time-Course of the Inflammatory Response During Sepsis M" Z4 o+ z6 d5 n+ {1 X! F
7. 7. Animal models and transgenesis in biotechnology
- i( A# ~6 j3 k8. 8. Embryonic and adult stem cells in regenerative medicine I.! ~" K2 z3 p5 p3 x% }% S
8.1 Embryonic stem cells
# S5 N" h$ H3 M& T3 b2 y7 A+ E8.2 Somatic cell reprogramming into pluripotent stem cells. {1 B1 d0 z" A2 u' C) E
8.3 Adult stem cells
7 [8 H( o! J+ C9. 9. Embryonic and adult stem cells in regenerative medicine II.) N' Z- s- n9 n
9.1 Pluripotent stem cells for regenerative medicine
# a8 ], {+ k( K$ y; I8 o( P* ]9.2 Clinical application of stem cells: D2 f7 i3 j5 h) P- P
9.3 Stem cell therapy to cure various diseases @9 p6 U0 _# }" H7 J
10. 10. Cell Cycle and Cancer Therapy, p53 I.# X" ^/ W/ c, |: r# S6 M2 I3 k+ X
10.1 Cell Cycle3 D0 s8 t9 h% y2 I) K$ I
10.2. Mitogenic Signaling in Eukaryotic Cell Controls the Rate of Cell Division
- z, X7 u! G2 `3 y7 y7 F10.3. Biochemical Events of Cell-cycle – in M Phase
( L2 x% G& I# l0 v/ {8 m0 t10.4. Protooncogenes" d9 @4 |' `- }2 ?' O& a- u
10.5. ErbB/HER Receptors j, X9 V) Z% E0 u
10.6. Therapeutic targets
! y, j6 O7 @! D1 N/ S! U$ E11. 11. Cell Cycle and Cancer Therapy, p53 II.
7 d+ T# ]& H1 N4 ?: C3 v! z11.1. Tumor Suppressor Genes and p53* L2 P! e. k. N* v6 i% b M
11.2. Biochemical Pathways of Apoptosis and its Therapeutic Utilization
. d. g1 `4 G! D2 {/ Q1 G" |12. 12. Gene Silencing Technologies.
1 Z8 l$ W2 S% ^% R12.1 Introduction0 q) O' x8 D c0 m4 Q! i
12.2 Action of antisense oligonucleotides
$ f/ ^3 q; @# x" R# ~/ n' p1 m' E9 ?( \) J( F12.3 Chemical modifications of gene silencing oligonucleotides; general considerations" |4 c8 X [4 r, F; N5 D# V0 _5 k
12.4 Inhibition of transcription by triple helix forming oligonucleotides) ` I' y$ K& X+ K
12.5 Gene silencing by ribozymes
: ^/ M7 d- V) t1 R3 E12.6 Gene silencing with short RNA fragments
; v& I, b0 C" m2 C* e12.7 Important final note
' f3 E* z' T, ]3 D( }5 x0 K6 r {8 r: g/ h& R: V# o
[hide][/hide] |
附件: 你需要登录才可以下载或查看附件。没有帐号？注册
-
总评分: 威望 + 5
包包 + 20
查看全部评分
|
发表于 2014-1-3 16:18
